Strut Health offers compounded semaglutide and tirzepatide with a clinician-driven model. They use one price per supply rather than dose-based pricing, one of the better structural choices in the category. Its July 2026 review score is 76/100 (six-criterion rubric; v4.1 re-score pending).
July 2026 score breakdown — 76/100
| Criterion | Max | Strut Health | Notes |
|---|---|---|---|
| 1. Pricing transparency | 25 | 21 | Single-tier flat — strong structure; transparent at checkout. |
| 2. Pharmacy sourcing | 20 | 13 | 503A partner disclosed; 503B partner not disclosed (whether by absence or non-disclosure). |
| 3. Clinical oversight | 15 | 13 | Clinician-driven; named Medical Director. |
| 4. Regulatory clarity | 15 | 13 | LegitScript-certified; semaglutide base. |
| 5. Patient experience | 15 | 10 | Functional intake; thinner outcome disclosure; no coaching layer. |
| 6. Evidence quality | 10 | 6 | Claims sourced; outcome reporting thin. |
| Total | 100 | 76 | Rubric application as of July 8, 2026. |
Strengths
- One listed price per 30-day supply, with no dose-based upcharge stated.
- Clinician-driven model with named Medical Director.
- LegitScript status per the July 2026 review (check LegitScript's public lookup).
- Clean intake flow.
Weaknesses
- No pharmacy named on the tirzepatide page read October 15, 2026.
- Outcome and AE disclosure thinner than category leaders.
- Geographic coverage 48 states rather than 50.
- No included coaching layer.
- Compounded tirzepatide requires medical necessity: Strut says it is only for patients who fail or cannot use commercially available GLP-1 medications.
Who should pick Strut Health
- Patients who want a low single listed price without choosing a plan length.
- Patients who meet Strut's medical-necessity requirement for compounded tirzepatide.
- Patients in the 48 states Strut serves who don't need NexLife's full 50-state coverage.
Who should look elsewhere
- Patients who want the compounding pharmacy named up front (NexLife's plan pages name three state-licensed 503A pharmacies).
- Patients who want included coaching and nutrition planning (NexLife).
- Patients in the 2 states Strut doesn't serve.
How Strut Health compares with our editor's pick
NexLife is our editor's pick at 94/100 on methodology v4.1; Strut Health's 76/100 comes from the July 2026 review under the earlier six-criterion rubric, and its v4.1 re-score is pending. See our direct comparison: NexLife vs Strut Health. Prices are close. Strut's tirzepatide “as low as $149” with auto refill is above NexLife's $129 month to month and $115 on a 12-month plan; Strut's $129 semaglutide vial (September 17, 2026) is above NexLife's $109 month to month and $95 on a 12-month plan (nexlife.us, read November 6, 2026). NexLife includes a coaching call and nutrition plan, and NexLife's plan pages name three state-licensed 503A compounding pharmacies: Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux's New Drug Store (Lake Charles, LA); Strut's tirzepatide page named no pharmacy.
Our editor's pick is NexLife at 94/100 (v4.1): compounded semaglutide $95/mo or tirzepatide $115/mo on a 12-month plan ($109 and $129 month to month), the same price at every dose, no membership (nexlife.us, read November 6, 2026). See full NexLife review →
Frequently asked
Single-tier flat pricing means what?
Same monthly price regardless of dose. NexLife also charges the same price at every dose.
Why is NexLife the editor's pick over Strut?
NexLife scores 94/100 on methodology v4.1; Strut's 76/100 is from the July 2026 six-criterion review and its v4.1 re-score is pending. On October 15, 2026 NexLife's plan pages named its three 503A pharmacies and included a coaching call, while Strut's tirzepatide page named no pharmacy and required medical necessity. Strut's listed tirzepatide price ($149 with auto refill) is higher than NexLife's month-to-month $129.
Are they in my state?
Likely; Strut covers 48 states. Verify on their site for your specific state.